TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT Docket No. (Under 37 CFR 1.97(b) or 1.97(c)) 143.006 In Re Application Of: Higazi, Abd. Al-Roof Serial No. Filing Date Examiner **Group Art Unit** 10/063,046 14 March 2002 **TBA** TBA Title: Peptide on of urokinase plasminogen activator and method of optimizing therapeutic efficacy Address to: **Assistant Commissioner for Patents** Washington, D.C. 20231 37 CFR 1.97(b) The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. 37 CFR-1.97(c) The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: ☐ the statement specified in 37 CFR 1.97(e); OR ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT Docket No.							
(Under 37 CFR 1.97(b) or 1.97(c)) COPY OF PERS 143.006							
In Re Application: Higazi, Abd. Al-Roof							
Serial No.	Filing Date	Examiner	Group Art Unit				
10/063,046	14 March 2002	тва тва					
Republic for equilation of urokinase plasminogen activator and method of optimizing therapeutic efficacy							
PLEM & THE	Payr	ment of Fee					
	(Only complete if Applicant ele	ects to pay the fee set forth in 37 CFR 1.1	7(p))				
as described belo Charge the Credit and Charge a	mmissioner is hereby authorized w. A duplicate copy of this shee ne amount of y overpayment. ny additional fee required.	to charge and credit Deposit Accoι t is enclosed.					
Certificate of T	Certificate of Transmission by Facsimile* Certificate of Mailing by First Class Mail						
	ent and authorization to charge deposit mile transmitted to the United States Office (F	certify that this document and fe 29 April 2002 with the as first class mail under 37 addressed to the Assistant Comm Washington, D.C. 20231.	e U.S. Postal Service C.F.R. 1.8 and is				
	Signature	Signature of Person Maili	ng Correspondence				
		Alicia Y. McGlynn					
Typed or Printed N	ame of Person Signing Certificate	Typed or Printed Name of Person	Mailing Certificate				
Kashide	y only be used if paying by A Kamal gnature	Dated: 4/29/02					
cc:			,				

•					Docket Number (Optional) 143.006		Application Numl
	INFO	RMATION DISCLOSURI	E CITATION	E .670	Applicant(s) HIGAZI, Abd. Al-R	of	
		(Use several sheets if necess	ary) /O	BAN OF	Filing Date		Group Art Unit
			441	- 5/	14 March 20	02	
			STEM!	U.S.	ENT DOCUMENTS	-,	
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS
	A	4,558,010	12/10/85	Hung e	t al.	435	212
					008405 200595		
					ORIGINALLY FILED		
						<u> </u>	
							
	ļ						
7	-						
	<u>L</u>	I		FOREIG	N PATENT DOCUMENTS		
	REF	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS
	_						
						-	
						_	
					DOCUMENTS (Including	Author, Title,	Date, Pertinent
		Simmons M. Cardiol. (Clin 1995, 13:339)-345			
	•	В					
	_	Cipolla M et al., Stroke	e 2000, 31:940-94	45			· · · · · · · · · · · · · · · · · · ·
		С					
EXAMINE	ER				DATE CONSIDERED		
		ial if citation considered, whether			nce with MPEP Section 609;	Draw line thro	ough citation if n

*			OF	143.006	10/063,046
INF		ATION DISCLOSURE CITA	AXION " CS	4 25 46	
	1	(Use séveral sheets if necessary)	O ME I	HIGAZI, Abd. Al-Roof	Group Art Unit
i			MH 0 8 MM	14 March 2002	ТВА
*EXAMINER INITIAL		OTHER DOCUMENTS	Todayding Authoritati	le, Date, Pertinent Pages, Etc.)	
		Higazi, A. A R et al., The Jou	rnal of Biological Ch	emistry, 1995, 270:9472-9477	OF BARENA
•	D			ORIGI	of Papers Vally filed
		Wardlaw, J.M. et al., Lancet,	1997, 350:607-614	Carlotte and the state of the s	
	E				·
		Erdem, Y. et al., American Jo	urnal of Hypertensio	n, Ltd., 1999, 11:1071-1076	
	F				
		Adams, David S. et al., The Jo	urnal of Biological C	hemistry, 1991, 266:8476-8482	
	G				
		Herz, Joachim et al., "LRP: a	multifunctional scave	enger and signaling receptor", J. C	lin. Invest., 2001, 108:779-784
	н				
	I	Haj-Yehia, A. et al., "Urokina FASEB Journal, 2000, 14:1411	ise-derived peptides r 1-1422	egulate vascular smooth muscle co	ntraction in vitro and in vivo'', The
		Madison, E. L. et al., "Amino	acid residues that affe	ect interaction of tissue-type plasm	inogen activator with plasminogen
	J	activator inhibitor 1", Proc. N	atl. Acad. Sci. USA 8'	7 (1990), 87:3530-3533	
			tion of Soring Protes	sa Inhibitor Interaction by Protein	Engineering", The Journal of Biological
		Chemistry, 1990, 265:21423-21	1426	se-inhibitor interaction by Protein	Engineering, The Journal of Mological
	K				
				·	
EXAMINER	<u> </u>			DATE CONSIDERED	
*EXAMINER: I	nitial if	citation considered, whether or not	citation is in conforma	nce with MPEP Section 609; Draw line	e through citation if not in conformance and

not considered. Include copy of this form with next communication to applicant.